<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519243</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-131-2</org_study_id>
    <nct_id>NCT03519243</nct_id>
  </id_info>
  <brief_title>Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis</brief_title>
  <official_title>Randomized Open-Label Comparative Study of the Efficacy and Safety of BCD-131 (JSC BIOCAD, Russia) and Mircera (F. Hoffmann-La Roche Ltd, Switzerland) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BCD-131 is pegylated darbepoetin beta. BCD-131-2 is International Multicenter Randomized
      Open-Label Comparative Study (Phase II) of the Efficacy and Safety of BCD-131 and Mircera in
      Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis of the study is that the efficacy of BCD-131 is equivalent to that of Mircera®
      based on the analysis of the primary endpoint (changes in the Hb level over the period of
      evaluation as compared to the baseline Hb level ) during the 21-week period of treatment.

      This study is a study of the maintenance treatment of anemia. The study will include up to
      100 dialysis patients with stage 5D chronic kidney disease, established efficacy of dialysis
      and renal anemia without other causes of anemia, receiving erythropoiesis-stimulating agents
      (ESA) and reaching target hemoglobin levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Actual">December 10, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period</measure>
    <time_frame>Baseline - measurements on Screening (weeks -4 - 0) and on day 1; Evaluation period - weekly measures on weeks 21 to 23</time_frame>
    <description>The baseline hemoglobin will be calculated as the arithmetic mean of hemoglobin values obtained at screening and at Visit 1. The final hemoglobin value during the evaluation period will be calculated as the arithmetic mean of hemoglobin values obtained at Week 21 and Week 23.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients Who Developed AEs/SAEs That, in the Investigator's Opinion, Are Related to BCD-131</measure>
    <time_frame>Week 23</time_frame>
    <description>The proportion of patients, in each group, who developed СТСАЕ v. 4.03 Grade 3-4 AEs that, in the Investigator's opinion, are related to BCD-131
- the proportion of patients, in each group, who discontinued the study due to AEs/SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of BAb- and NAb-positive Patients</measure>
    <time_frame>Week 9, 23</time_frame>
    <description>Blood sampling for immunogenicity assessment (BAbs and NAbs) will be performed in all the patients included in the study before the first injection and then at Week 9 and Week 23.
The immunogenicity endpoints will be analyzed after the completion of all periods of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-672 Hour)</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1</time_frame>
    <description>Area under the concentration curve from the moment of injection to 672 h [28 days])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-∞)</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21</time_frame>
    <description>Area under the concentration curve from the moment of injection to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21</time_frame>
    <description>Maximum serum concentration of the drug product) after the first injection of the test/reference drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC(0-672 Hour)</measure>
    <time_frame>3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1</time_frame>
    <description>Area under the effect curve from the drug injection to 672 h [28 days]) based on the change in the absolute reticulocyte count after the first injection of the test/reference drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AC-Emax</measure>
    <time_frame>day 28</time_frame>
    <description>Maximum absolute reticulocyte count after the first injection of BCD-131/Mircera®</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>BCD-131 1,05 mcg/kg * conversion ratio</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneously monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131 1,7 mcg/kg * conversion ratio</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneously monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131 2,75 mcg/kg * conversion ratio</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneously monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mircera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneously monthly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-131</intervention_name>
    <description>subcutaneously monthly</description>
    <arm_group_label>BCD-131 1,05 mcg/kg * conversion ratio</arm_group_label>
    <arm_group_label>BCD-131 1,7 mcg/kg * conversion ratio</arm_group_label>
    <arm_group_label>BCD-131 2,75 mcg/kg * conversion ratio</arm_group_label>
    <other_name>pegylated darbepoetin beta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mircera</intervention_name>
    <description>subcutaneously monthly</description>
    <arm_group_label>Mircera</arm_group_label>
    <other_name>Methoxy polyethylene glycol-epoetin beta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent.

          -  Men and women aged from 18 to 75 years (inclusive) on the day of signing informed
             consent;

          -  End-stage kidney disease.

          -  Need for dialysis for at least 3 months before signing informed consent.

          -  Need for at least 12 hours on standard dialysis procedure weekly.

          -  rHuEpo (epoetin alpha, epoetin beta, darbepoetin alpha) administration for at least 3
             months before signing informed consent.

          -  Regular rHuEpo (epoetin alfa, epoetin beta, darbepoetin alfa) administration 1, 2 or 3
             times a week (stable dose, stable frequency) before signing informed consent.

          -  Target hemoglobin level (100-120 g/l) for at least 3 months before signing informed
             consent.

          -  Effective dialysis dose index (Kt/v) ≥1.2 for patients receiving hemodialysis and
             (Kt/v) ≥1.7 for patients receiving peritoneal dialysis.

          -  TSAT ≥20%, Serum ferritin &gt;200 ng/ml.

          -  Patients and their sexual partners with childbearing potential must implement reliable
             contraceptive measures during all the study treatment, starting 4 weeks prior to the
             administration of the first dose of investigational product until 4 weeks after the
             last dose of investigational product. This requirement does not apply to participants
             who have undergone surgical sterilization. Reliable contraceptive measures include two
             methods of contraception, including one barrier method/

          -  Patients should be able to follow the Protocol procedures

        Exclusion Criteria:

          -  Any other causes of anemia except for renal anemia, including folate and B12
             deficiency, chronic blood loss, aluminium intoxication, sickle-cell anemia, chronic
             disease anemia (CRP above 20 mg/l), refractory anemia with blast cells in peripheral
             blood.

          -  Lupus nephritis of kidney disease due to systemic vasculitis.

          -  Platelet count below 100х10^9 cells/l.

          -  Scheduled kidney transplant during study participation period.

          -  Hypersensitivity to darbepoetin alfa or of any components of study drugs, or to Fe
             (III)-hydroxide-sucrose complex.

          -  Vaccination less than 8 weeks before signing informed consent.

          -  Liver cirrhosis with portal hypertension and/or splenomegaly and/or ascitis.

          -  HIV infection, active HBV, HCV.

          -  ALT, AST level above 3x ULN.

          -  Congestive heart failure (Grade IV NYHA)

          -  Resistant arterial hypertension.

          -  Unstable angina.

          -  Hemoglobinopathy, MDS, hematologic malignancy, PRCA.

          -  Severe secondary hyperparathyroidism.

          -  Gastrointestinal bleeding history.

          -  Thrombotic events history (myocardial infarction, stroke, TIA, DVT, PATE) less than 6
             months before signing informed consent.

          -  Seizures, including epilepsy.

          -  Major surgery in less than 1 month before signing informed consent

          -  Blood transfusions in less than 3 months before signing informed consent.

          -  Acute inflammatory diseases or exacerbations of chronic inflammation.

          -  Severe psychiatric disorders and suicidal ideation and suicidal behavior.

          -  History of malignancy, excluding appropriately treated basal cell carcinoma or
             cervical carcinoma in situ.

          -  Alcohol or drug abuse.

          -  Simultaneous participation in other trials or in less than 3 months before signing
             informed consent

          -  Pregnancy of breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Ivanov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>JCS BIOCAD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City Clinical Hospital №9</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Mariin Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B.Braun Avitum Russland Clinics Ltd.</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <results_first_submitted>May 29, 2019</results_first_submitted>
  <results_first_submitted_qc>May 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2019</results_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03519243/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03519243/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BCD-131 1,05 mcg/kg * Conversion Ratio</title>
          <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
        </group>
        <group group_id="P2">
          <title>BCD-131 1,7 mcg/kg * Conversion Ratio</title>
          <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
        </group>
        <group group_id="P3">
          <title>BCD-131 2,75 mcg/kg * Conversion Ratio</title>
          <description>Subcutaneously monthly
BCD-131: subcutaneously monthly</description>
        </group>
        <group group_id="P4">
          <title>Mircera</title>
          <description>subcutaneously monthly
Mircera: subcutaneously monthly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="0">The dose level was not studied due to the dose level l.7 µg/kg demonstrated the sufficient PD effect</participants>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BCD-131 1,05 mcg/kg * Conversion Ratio</title>
          <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
        </group>
        <group group_id="B2">
          <title>BCD-131 1,7 mcg/kg * Conversion Ratio</title>
          <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
        </group>
        <group group_id="B3">
          <title>Mircera</title>
          <description>subcutaneously monthly
Mircera: subcutaneously monthly</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="48" upper_limit="64"/>
                    <measurement group_id="B2" value="54" lower_limit="46" upper_limit="63"/>
                    <measurement group_id="B3" value="47" lower_limit="35" upper_limit="58"/>
                    <measurement group_id="B4" value="55" lower_limit="46" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belarus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period</title>
        <description>The baseline hemoglobin will be calculated as the arithmetic mean of hemoglobin values obtained at screening and at Visit 1. The final hemoglobin value during the evaluation period will be calculated as the arithmetic mean of hemoglobin values obtained at Week 21 and Week 23.</description>
        <time_frame>Baseline - measurements on Screening (weeks -4 - 0) and on day 1; Evaluation period - weekly measures on weeks 21 to 23</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131 1,05 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O2">
            <title>BCD-131 1,7 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O3">
            <title>Mircera</title>
            <description>subcutaneously monthly
Mircera: subcutaneously monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period</title>
          <description>The baseline hemoglobin will be calculated as the arithmetic mean of hemoglobin values obtained at screening and at Visit 1. The final hemoglobin value during the evaluation period will be calculated as the arithmetic mean of hemoglobin values obtained at Week 21 and Week 23.</description>
          <units>g/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.25" lower_limit="-12" upper_limit="0.5"/>
                    <measurement group_id="O2" value="3.5" lower_limit="-7" upper_limit="14"/>
                    <measurement group_id="O3" value="-2.75" lower_limit="-9.5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients Who Developed AEs/SAEs That, in the Investigator's Opinion, Are Related to BCD-131</title>
        <description>The proportion of patients, in each group, who developed СТСАЕ v. 4.03 Grade 3-4 AEs that, in the Investigator's opinion, are related to BCD-131
- the proportion of patients, in each group, who discontinued the study due to AEs/SAEs</description>
        <time_frame>Week 23</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131 1,05 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O2">
            <title>BCD-131 1,7 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O3">
            <title>Mircera</title>
            <description>subcutaneously monthly
Mircera: subcutaneously monthly</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients Who Developed AEs/SAEs That, in the Investigator's Opinion, Are Related to BCD-131</title>
          <description>The proportion of patients, in each group, who developed СТСАЕ v. 4.03 Grade 3-4 AEs that, in the Investigator's opinion, are related to BCD-131
- the proportion of patients, in each group, who discontinued the study due to AEs/SAEs</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of BAb- and NAb-positive Patients</title>
        <description>Blood sampling for immunogenicity assessment (BAbs and NAbs) will be performed in all the patients included in the study before the first injection and then at Week 9 and Week 23.
The immunogenicity endpoints will be analyzed after the completion of all periods of the study.</description>
        <time_frame>Week 9, 23</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131 1,05 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O2">
            <title>BCD-131 1,7 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O3">
            <title>Mircera</title>
            <description>subcutaneously monthly
Mircera: subcutaneously monthly</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of BAb- and NAb-positive Patients</title>
          <description>Blood sampling for immunogenicity assessment (BAbs and NAbs) will be performed in all the patients included in the study before the first injection and then at Week 9 and Week 23.
The immunogenicity endpoints will be analyzed after the completion of all periods of the study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-672 Hour)</title>
        <description>Area under the concentration curve from the moment of injection to 672 h [28 days])</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131 1,05 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O2">
            <title>BCD-131 1,7 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O3">
            <title>Mircera</title>
            <description>subcutaneously monthly
Mircera: subcutaneously monthly</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-672 Hour)</title>
          <description>Area under the concentration curve from the moment of injection to 672 h [28 days])</description>
          <units>(mmol/L)*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51744.45" lower_limit="31201.8" upper_limit="87463.5"/>
                    <measurement group_id="O2" value="73948.8" lower_limit="57057.15" upper_limit="133730.25"/>
                    <measurement group_id="O3" value="89409.3" lower_limit="35389.95" upper_limit="166699.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-∞)</title>
        <description>Area under the concentration curve from the moment of injection to infinity</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131 1,05 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O2">
            <title>BCD-131 1,7 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O3">
            <title>Mircera</title>
            <description>subcutaneously monthly
Mircera: subcutaneously monthly</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-∞)</title>
          <description>Area under the concentration curve from the moment of injection to infinity</description>
          <units>(mmol/L)*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65150.045" lower_limit="43463.791" upper_limit="91305.66"/>
                    <measurement group_id="O2" value="81698.001" lower_limit="63442.206" upper_limit="142665.693"/>
                    <measurement group_id="O3" value="96259.513" lower_limit="46985.695" upper_limit="192570.672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Maximum serum concentration of the drug product) after the first injection of the test/reference drug</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131 1,05 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O2">
            <title>BCD-131 1,7 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O3">
            <title>Mircera</title>
            <description>subcutaneously monthly
Mircera: subcutaneously monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum serum concentration of the drug product) after the first injection of the test/reference drug</description>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.3" lower_limit="148.7" upper_limit="407.1"/>
                    <measurement group_id="O2" value="231.9" lower_limit="187.2" upper_limit="488.2"/>
                    <measurement group_id="O3" value="617.6" lower_limit="130.6" upper_limit="943.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUEC(0-672 Hour)</title>
        <description>Area under the effect curve from the drug injection to 672 h [28 days]) based on the change in the absolute reticulocyte count after the first injection of the test/reference drug</description>
        <time_frame>3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131 1,05 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O2">
            <title>BCD-131 1,7 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O3">
            <title>Mircera</title>
            <description>subcutaneously monthly
Mircera: subcutaneously monthly</description>
          </group>
        </group_list>
        <measure>
          <title>AUEC(0-672 Hour)</title>
          <description>Area under the effect curve from the drug injection to 672 h [28 days]) based on the change in the absolute reticulocyte count after the first injection of the test/reference drug</description>
          <units>(cells*10^9)*h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7210.479" spread="5465.155"/>
                    <measurement group_id="O2" value="11274.380" spread="12460.177"/>
                    <measurement group_id="O3" value="12131.820" spread="15613.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AC-Emax</title>
        <description>Maximum absolute reticulocyte count after the first injection of BCD-131/Mircera®</description>
        <time_frame>day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131 1,05 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O2">
            <title>BCD-131 1,7 mcg/kg * Conversion Ratio</title>
            <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
          </group>
          <group group_id="O3">
            <title>Mircera</title>
            <description>subcutaneously monthly
Mircera: subcutaneously monthly</description>
          </group>
        </group_list>
        <measure>
          <title>AC-Emax</title>
          <description>Maximum absolute reticulocyte count after the first injection of BCD-131/Mircera®</description>
          <units>(cells*10^9)/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.650" spread="29.185"/>
                    <measurement group_id="O2" value="107.047" spread="38.615"/>
                    <measurement group_id="O3" value="154.753" spread="58.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>25 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BCD-131 1,05 mcg/kg * Conversion Ratio</title>
          <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
        </group>
        <group group_id="E2">
          <title>BCD-131 1,7 mcg/kg * Conversion Ratio</title>
          <description>subcutaneously monthly
BCD-131: subcutaneously monthly</description>
        </group>
        <group group_id="E3">
          <title>Mircera</title>
          <description>subcutaneously monthly
Mircera: subcutaneously monthly</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic Heart Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>non-Q wave myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes. Diabetic foot syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter-associated infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>fracture of the left ankle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>consequence of stroke</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>subcutaneous tissue</sub_title>
                <description>Infection of postsurgical subcutaneous seroma</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous Access Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Phlebitis of the fistula vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>arteriovenous fistula stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ECG changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>lymphocytes decrease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>leukocytes decrease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>neutrophils decrease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>lymphocytes increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>arterial pressure increase</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>systolic blood pressure increase (isolated)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>dyastolic blood pressure increase (isolated)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linkova Iuliia</name_or_title>
      <organization>BIOCAD</organization>
      <phone>+7 (495) 992 66 28 ext 930</phone>
      <email>linkova@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

